FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis

The US FDA has approved icotrokinra (Icotyde; Johnson & Johnson), a first-in-class oral IL-23 receptor antagonist, for the treatment of moderate to severe plaque psoriasis in adults and adolescents 12 years and older weighing at least 40 kg. The once-daily oral peptide introduces a mechanistically distinct option in a therapeutic landscape largely defined by injectable biologics.¹

"It is a very exciting day for patients [with psoriasis] and dermatology as a whole. The FDA approval of icotrokinra marks an immediate elevation of the standard of care for oral treatment of plaque psoriasis, making it a transformative medicine in our clinics,” Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, and Dermatology Times editor in chief, said in an exclusive statement. “Icotrokinra uses a unique cyclic peptide structure to tightly bind at picomolar affinity the IL-23 receptor and shut down a key signaling pathway driving plaque psoriasis. Icotrokinra brings an exciting, biologic-level efficacy treatment to patients [with psoriasis] who may desire oral treatment, while targeting a familiar pathway with a track record of high levels of safety."

Unlike currently available IL-23 inhibitors that target the cytokine itself, icotrokinra selectively blocks the IL-23 receptor. This approach may offer a more proximal interruption of the inflammatory signaling cascade while maintaining the convenience of oral administration. For clinicians, this dual advantage—mechanistic precision and ease of use—may influence earlier adoption of systemic therapy in appropriate patients.

“[Icotrokinra] delivers something unique in psoriasis treatment, combining skin clearance with a favorable safety profile in a once-daily pill, making it an easy addition to a patient’s routine,” Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health, said in the news release. She also pointed to evolving standards: “With new guidance from the International Psoriasis Council that clarifies when to move beyond cycling on topical treatments to systemic therapy, an innovative option like [icotrokinra] is a potential game-changer for many adult and adolescent patients.”

Strong Phase 3 Efficacy With Placebo-Like Safety Profile

Approval was based on the ICONIC clinical development program, which included 4 phase 3 trials enrolling approximately 2500 patients. The program is notable for its breadth, simultaneously evaluating adults and adolescents, as well as patients with involvement of high-impact areas such as the scalp and genital regions.

In head-to-head superiority trials against an active comparator, icotrokinra demonstrated robust efficacy:

• Approximately 70% of patients achieved Investigator Global Assessment scores of 0 or 1 (clear or almost clear skin) at week 16.
• Approximately 55% achieved a Psoriasis Area and Severity Index 90 response at week 16.

These results are consistent with high levels of skin clearance observed with IL-23 pathway inhibition, though the oral formulation distinguishes icotrokinra from its injectable counterparts.

From a safety perspective, rates of adverse reactions were within 1.1% of placebo through week 16, and no new safety signals were identified through 52 weeks. Although longer-term surveillance will be essential, these findings suggest a favorable tolerability profile consistent with targeted immunomodulatory therapy.

Persistent Unmet Needs in Psoriasis Care

Psoriasis affects more than 8 million individuals in the United States, with moderate to severe disease often requiring systemic treatment. Despite therapeutic advances, clinicians continue to navigate challenges related to adherence, patient preferences, and treatment fatigue, particularly with injectable agents.²

The International Psoriasis Council recommends transitioning to systemic therapy after failure of 2 adequate topical treatment cycles.³ However, in practice, delays are common, often due to concerns about safety, administration burden, or patient reluctance.

“Finding the right treatment can take time, during which people with psoriatic disease should be considering multiple factors, from efficacy to safety to how the treatment fits into their everyday life,” Leah M. Howard, JD, president and CEO of the National Psoriasis Foundation, said in the news release. “The approval of a novel systemic therapy changes the conversation about treatment options for our community.”

Implications for Treatment Algorithms

The introduction of icotrokinra adds a new dimension to psoriasis management, potentially reshaping how clinicians approach systemic therapy. Its efficacy profile suggests it may compete with established biologics, whereas its oral route could position it as an appealing alternative to both traditional systemic agents and injectable biologics.

John Reed, MD, PhD, executive vice president of research and development at Johnson & Johnson, emphasized the broader significance: “[Icotrokinra] is a fundamentally different treatment with the potential to redefine what physicians and patients can expect from psoriasis treatment.”¹

Key considerations for clinicians will include how icotrokinra performs in biologic-experienced populations, its long-term durability, and its indirect comparison with established IL-23 monoclonal antibodies. Cost, payer coverage, and patient adherence will also play central roles in determining its place in therapy.

Access and Support Considerations

Johnson & Johnson has announced a patient support program, ICOTYDE withMe, designed to assist with access, affordability, and education. The program includes cost support options and nurse guidance, which may help mitigate barriers to initiation and continuation of therapy.

A Potential Shift in Expectations

The approval of icotrokinra underscores a broader evolution toward targeted, patient-friendly therapies in dermatology. By combining oral administration with high levels of efficacy and a favorable safety profile, it may help bridge a long-standing gap between convenience and clinical outcomes.

For clinicians, the availability of an oral IL-23 receptor antagonist introduces new flexibility in tailoring treatment strategies. As real-world experience accumulates, icotrokinra’s role in the psoriasis treatment strategy will become clearer, but early evidence suggests it may significantly expand what is achievable for patients with moderate to severe disease.

References

1. FDA approval of Icotyde (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. News release. Johnson & Johnson. March 18, 2026. Accessed March 18, 2026. https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide
2. Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis (Auckl). 2025;15:175-183. doi:10.2147/PTT.S519420
3. Strober BE, Blauvelt A, van de Kerkhof PCM, et al. Establishing consensus on defining failure of topical therapy in psoriasis: recommendations from the International Psoriasis Council. J Am Acad Dermatol. 2026;94(1):372-375. doi:10.1016/j.jaad.2025.08.116